BioJapan: Policy Changes Key To Rebuilding Japan’s Competitiveness
A range of speakers from government, regulators and the industry lay out at the BioJapan meeting in Yokohama the major challenges facing Japan's biopharma sector as it looks to regain its competitiveness on the world stage.
Scrip - October 9, 2026

Medical Microinstruments Raises $125M In Series D To Scale Robotic Microsurgery
Medical Microinstruments raised $125m in Series D funding, led by BioStar Capital. The firm will use the funds to expand sales of its FDA-cleared Symani robotic microsurgery system, which has about 50 installations and 3,500 procedures, and to fund clinical trials, including an Alzheimer’s study.
Medtech Insight - October 8, 2026

Execs On The Move: September 28–October 2, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 8, 2026

German Medtechs’ 10-Point Plan Augurs ‘Autumn Of Reform’
BVMed set out its priorities for the government’s Medtech Dialog and growth strategy for industry against a backdrop of persistently weak annual performances amid a claimed fall in medtech company numbers.
Medtech Insight - October 8, 2026

First Devices Selected For EU Joint Assessment Process That Has Faced Pharma Skepticism
Edwards and Highlife’s mitral valve replacement systems will receive health technology assessment (HTA) at an EU level via a process designed for high-risk devices that can address unmet needs.
Medtech Insight - October 8, 2026

Hair Care ‘Skinification’ Trend Accelerating, Says Unilever R&D Chief
Unilever is accelerating hair care’s shift toward 'skinification,' using advances in hair science to develop products focused on prevention, protection and performance.
HBW Insight - October 8, 2026

AESGP Switch Day: Too Much Focus On Risk In Rx-To-OTC Reclassification Decisions
Former US FDA advisory committee chair Eric Brass told the AESGP switch conference in Brussels that switch decisions focus too much on risk, citing emergency contraception in Germany and heartburn drugs in the US as examples of the benefits at stake.
HBW Insight - October 8, 2026

People On The Move: Appointments At Schwabe Group, Stada, Venture Life
A round-up of the latest moves in Europe's consumer health sector: Schwabe Group names chief commercial officer; Stada appoints global AI and digital leader; Venture Life names successor to CEO Jerry Randall.
HBW Insight - October 8, 2026

Alvotech Broadens US Supply Footprint With Lotte Tie-Up
Marking another step in broadening its manufacturing network, Alvotech has announced a long-term partnership with Lotte Biologics that will see the firm produce drug substance for multiple antibody biosimilars at its US facilities in Syracuse, New York.
Generics Bulletin - October 8, 2026

Kamada Expands Biosimilar Portfolio With Stelara And Clexane Rival Launches In Israel
Kamada has launched ustekinumab and enoxaparin biosimilars in Israel, though its current $10m 2028 revenue target is significantly below the $40m peak it projected in 2022.
Generics Bulletin - October 8, 2026

Desai Takes Aim At Canadian Biosimilars With Launch Of Palindrome Pharma
Former Apotex chief executive Jeremy Desai is launching a new Canadian biosimilars company under the banner of Palindrome Pharma.
Generics Bulletin - October 8, 2026

Rare To Blockbuster: Expansion Strategies In Non-Oncology Precision Medicine
Setmelanotide grew from $3m to $195m in annual sales by stretching one mechanism across rare and acquired obesity, and a handful of non-oncology precision medicines in the pipeline are now attempting the same trick on far larger patient populations.
In Vivo - October 7, 2026

MIT’s Barzilay Wants AI To Predict Who Responds
Since her 2014 breast cancer diagnosis, MIT's Regina Barzilay has built artificial intelligence tools for screening and drug discovery. Now she is developing AI to predict which patients will respond to which treatments.
In Vivo - October 7, 2026